Emmaus Life Sciences Past Earnings Performance
Past criteria checks 0/6
Emmaus Life Sciences has been growing earnings at an average annual rate of 47.9%, while the Pharmaceuticals industry saw earnings growing at 1.7% annually. Revenues have been growing at an average rate of 4% per year.
Key information
47.9%
Earnings growth rate
53.8%
EPS growth rate
Pharmaceuticals Industry Growth | 6.0% |
Revenue growth rate | 4.0% |
Return on equity | n/a |
Net Margin | -16.7% |
Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Emmaus Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 23 | 28 | -5 | 24 | 2 |
30 Jun 23 | 28 | -5 | 24 | 2 |
31 Mar 23 | 22 | -13 | 23 | 2 |
31 Dec 22 | 18 | -11 | 21 | 2 |
30 Sep 22 | 15 | -18 | 19 | 2 |
30 Jun 22 | 16 | -20 | 20 | 2 |
31 Mar 22 | 19 | -9 | 19 | 3 |
31 Dec 21 | 21 | -16 | 19 | 4 |
30 Sep 21 | 24 | -9 | 19 | 4 |
30 Jun 21 | 24 | -1 | 18 | 4 |
31 Mar 21 | 22 | -13 | 19 | 4 |
31 Dec 20 | 23 | 1 | 19 | 2 |
30 Sep 20 | 24 | 0 | 19 | 2 |
30 Jun 20 | 24 | -24 | 21 | 2 |
31 Mar 20 | 25 | -32 | 21 | 2 |
31 Dec 19 | 23 | -55 | 22 | 2 |
30 Sep 19 | 24 | -87 | 23 | 2 |
30 Jun 19 | 23 | -54 | 23 | 2 |
31 Mar 19 | 20 | -84 | 23 | 2 |
31 Dec 18 | 16 | -73 | 22 | 2 |
30 Sep 18 | 8 | -37 | 22 | 2 |
30 Jun 18 | 4 | -69 | 19 | 2 |
31 Mar 18 | 1 | -33 | 18 | 2 |
31 Dec 17 | 1 | -33 | 16 | 3 |
30 Sep 17 | 1 | -43 | 12 | 3 |
30 Jun 17 | 0 | -32 | 12 | 3 |
31 Mar 17 | 0 | -23 | 10 | 2 |
31 Dec 16 | 0 | -21 | 10 | 2 |
30 Sep 16 | 1 | -19 | 10 | 2 |
30 Jun 16 | 1 | -16 | 10 | 2 |
31 Mar 16 | 1 | -15 | 10 | 2 |
31 Dec 15 | 1 | -13 | 11 | 2 |
30 Sep 15 | 0 | -11 | 11 | 1 |
30 Jun 15 | 1 | -11 | 11 | 1 |
31 Mar 15 | 1 | -18 | 13 | 2 |
31 Dec 14 | 1 | -22 | 13 | 2 |
30 Sep 14 | 0 | -22 | 13 | 2 |
30 Jun 14 | 0 | -23 | 13 | 2 |
31 Mar 14 | 0 | -18 | 11 | 2 |
31 Dec 13 | 0 | -14 | 11 | 2 |
30 Sep 13 | 0 | -15 | 10 | 3 |
30 Jun 13 | 0 | -14 | 9 | 3 |
31 Mar 13 | 0 | -14 | 9 | 3 |
Quality Earnings: EMMA is currently unprofitable.
Growing Profit Margin: EMMA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EMMA is unprofitable, but has reduced losses over the past 5 years at a rate of 47.9% per year.
Accelerating Growth: Unable to compare EMMA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EMMA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: EMMA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.